| Literature DB >> 21675380 |
Meera Hameed1, Howard Dorfman.
Abstract
Primary malignant bone tumors are rare sarcomas with an estimated frequency of about 2900 new cases per year; they constitute less than 0.2% of all cancers diagnosed in the United States. The diagnosis and management of these neoplasms require a team approach, which includes orthopaedic surgeons, radiologists, pathologists, and oncologists. With this approach and current treatment modalities, the 5-year survival for the most common malignant bone tumors, osteosarcoma and Ewing sarcoma, are 70% and 60%, respectively. This review will summarize recent developments and advances in molecular pathogenesis of the more common primary malignant bone neoplasms.Entities:
Mesh:
Year: 2011 PMID: 21675380 DOI: 10.1053/j.semdp.2011.02.002
Source DB: PubMed Journal: Semin Diagn Pathol ISSN: 0740-2570 Impact factor: 3.464